Single arm, open label, signal seeking, phase IIa trial of the activity of eribulin in patients with advanced CD31 positive angiosarcoma and selected CD31 positive sarcomas
Phase of Trial: Phase II
Latest Information Update: 04 Jul 2019
Price : $35 *
At a glance
- Drugs Eribulin (Primary)
- Indications Haemangioendothelioma; Haemangiosarcoma; Sarcoma
- Focus Therapeutic Use
- Acronyms MoST Addendum 5
- 19 Mar 2019 Status changed from not yet recruiting to recruiting.
- 24 May 2018 Planned initiation date changed from 1 Jun 2018 to 1 Sep 2018.
- 25 Apr 2018 New trial record